November 2022 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

November 11, 2022 at 4:11 PM

Crystal Research Associates has issued a 17-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, cancer, covid19, coronovirus, covid-19, monkeypox

August 2022 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

August 5, 2022 at 4:02 PM

Crystal Research Associates has issued a 19-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, cancer, covid19, coronovirus, covid-19, monkeypox

April 2022 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

April 29, 2022 at 1:23 PM

Crystal Research Associates has issued a 15-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, cancer, covid19, coronovirus, covid-19

March 2022 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

March 14, 2022 at 6:22 PM

Crystal Research Associates has issued a 15-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, cancer, covid19, coronovirus, covid-19

November 2021 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

November 17, 2021 at 9:28 AM

Crystal Research Associates has issued a 13-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

GeoVax Enters Agreement with PNP Therapeutics for Solid Tumor Treatment

Posted by Karen Goldfarb

October 4, 2021 at 11:13 AM

Crystal Research Associates has issued a 6-page update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ) following its announcement of an Assignment and License Agreement with PNP Therapeutics, Inc. (“PNP”), granting GeoVax exclusive rights to develop and commercialize Gedeptin®, a novel patented product to treat solid tumors. 

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

August 2021 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

August 15, 2021 at 6:35 PM

Crystal Research Associates has issued a 15-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

May 2021 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

May 11, 2021 at 3:59 PM

Crystal Research Associates has issued an 16-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

March 2021 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

March 29, 2021 at 2:53 PM

Crystal Research Associates has issued an 14-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

February 2021 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

February 16, 2021 at 10:13 AM

Crystal Research Associates has issued an 11-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

 

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

New Research Released on Celsion Corporation (CLSN-NASDAQ)

Posted by Karen Goldfarb

December 9, 2020 at 3:35 PM

An Executive Informational Overview (EIO) is now available on Celsion Corporation, a fully integrated biopharmaceutical company focused on developing cancer therapies for difficult-to-treat forms of cancers. The 68-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Download Celsion Corporation  Initiation Report

Read More

Topics: biotech, immunotherapy, cancer, autoimmune, hepatocellular cancer, GEN-1, ovarian cancer, interleukin-12, IL-12, ThermoDox, primary liver cancer, celsion

November 2020 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

November 11, 2020 at 10:24 AM

Crystal Research Associates has issued a 12-page Quarterly Update on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVX-NASDAQ).

 

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

New Research Released on CEL-SCI Corporation (CVM-NYSE)

Posted by Karen Goldfarb

June 3, 2020 at 12:34 PM

An Executive Informational Overview (EIO) is now available on CEL-SCI Corporation, a clinical-stage biotechnology company developing immunotherapy technologies to treat cancer, autoimmune, and infectious diseases. The 86-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Download CEL-SCI Corporation Report

Read More

Topics: biotech, immunotherapy, CEL-SCI, infectious diseases, leaps, cancer, autoimmune, head and neck cancer, squamous cell carcinoma, rheumatoid arthritis, covid19, cervical dysplasia

May 2019 Update on GeoVax Labs, Inc. (GOVXD-OTC)

Posted by Karen Goldfarb

May 28, 2019 at 12:27 PM

Crystal Research Associates has issued an 11-page Quarterly Update on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVXD-OTC), detailing the Company's recent news and developments, anticipated clinical trial and regulatory filing milestones, and financial position. The report is available for download below.

Download Update

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv

April 2019 Update Issued on GeoVax Labs, Inc. (GOVX-OTC)

Posted by Karen Goldfarb

March 31, 2019 at 8:52 PM

Crystal Research Associates has issued a 15-page Quarterly Update on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVX-OTC), detailing the Company's recent news and developments, anticipated clinical trial and regulatory filing milestones, and financial position. The report is available for download below.

Download Update

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv

Content not found
Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Date

see all

Posts by Topic